Recent work in PD-L1 inhibitor resistant triple negative BC patients revealed that inhibition of TG2, restored T cell-dependent cytotoxicity by inhibiting expression of PD-L1 and CCL2 in PD-L1+ breast cancer cells [66]. Here, CCL2 is linked to breast cancer.